Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Eli Lilly is experiencing explosive growth ... However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept.

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Eli Lilly And Co (NYSE:LLY ... more than doubled to $3.11 billion from $1.41 billion a year ago. Sales of Verzenio (a breast cancer drug) increased 32% to $1.37 billion, and sales of diabetes ...

Eli Lilly's existing portfolio, excluding incretins, also has potential growth contributors. The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology ...

In particular, Lilly highlighted the momentum behind breast cancer med Verzenio and the SGLT2 inhibitor ... been updated with executive comments from Eli Lilly's fourth-quarter and full-year ...